drugset / Trial / NCT04522323
A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate MEDI5752 in combination with Lenvatinib (or Axitinib), in subjects with advanced renal cell carcinoma.
Timeline
- Start
- 2020-08-05
- Primary completion
- 2025-09-26
- Completion
- 2025-09-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Volrustomig | Monoclonal antibody | — | — |
| Background | Axitinib | Small molecule | — | — |
| Background | Lenvatinib | Small molecule | — | — |